Overview

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
To compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of treatment for chronic dry eye disease
Phase:
Phase 4
Details
Lead Sponsor:
Florida Eye Microsurgical Institute
Collaborator:
Bausch & Lomb Incorporated
Treatments:
Bromfenac
Cyclosporine
Cyclosporins
Ketorolac
Ketorolac Tromethamine